China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 000999.SZ

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.15

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio is 0.15 for the year ending December 31, 2023, a 543.85% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.02, a 69.45% change year over year.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.01, a 504.03% change year over year.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.00, a -5.91% change year over year.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.00, a -26.60% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
Shenzhen Stock Exchange: 000999.SZ

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

CEO Mr. Wen Duo Wu
IPO Date March 9, 2000
Location China
Headquarters Guanlan High-tech Park
Employees 20,318
Sector Health Care
Industries
Description

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.

Similar companies

000538.SZ

Yunnan Baiyao Group Co.,Ltd

USD 7.83

2.23%

000623.SZ

Jilin Aodong Pharmaceutical Group Co., Ltd.

USD 2.25

3.72%

000963.SZ

Huadong Medicine Co., Ltd

USD 4.53

2.64%

000423.SZ

Dong-E-E-Jiao Co.,Ltd.

USD 8.44

1.77%

002007.SZ

Hualan Biological Engineering Inc.

USD 2.17

2.25%

StockViz Staff

January 15, 2025

Any question? Send us an email